G R Wilkinson

发表

WHEELHOUSE AND BRIDGE DESIGN-A SHIPBUILDER'S APPRAISAL

G R Wilkinson, 1971 .

Plasma binding and transport of diazepam across the blood-brain barrier. No evidence for in vivo enhanced dissociation.

G R Wilkinson, G. Wilkinson, R K Dubey, 1989, The Journal of clinical investigation.

Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.

G R Wilkinson, A. Rane, G. Wilkinson, 1977, The Journal of pharmacology and experimental therapeutics.

Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites.

G R Wilkinson, H. Zhou, G. Wilkinson, 1989, The New England journal of medicine.

Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

G R Wilkinson, R. Kim, C. Wandel, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Brain uptake of benzodiazepines: effects of lipophilicity and plasma protein binding.

G R Wilkinson, S D Hall, R. Branch, 1988, The Journal of pharmacology and experimental therapeutics.

Commentary: a physiological approach to hepatic drug clearance.

G R Wilkinson, G. Wilkinson, D. Shand, 1975, Clinical pharmacology and therapeutics.

The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.

G R Wilkinson, J. Goldstein, S. D. de Morais, 1994, The Journal of biological chemistry.

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

G R Wilkinson, J. Goldstein, S. D. de Morais, 1994, Molecular pharmacology.

OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.

G R Wilkinson, R. Kim, M. Fromm, 1999, Drug metabolism and disposition: the biological fate of chemicals.

Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments].

G R Wilkinson, D M Roden, D. Roden, 1999, Circulation.

A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.

G R Wilkinson, P. Dayer, J. Goldstein, 1998, The Journal of pharmacology and experimental therapeutics.

Clearance approaches in pharmacology.

G R Wilkinson, G. Wilkinson, 1987, Pharmacological reviews.

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

G R Wilkinson, F. Greco, G. Wilkinson, 1984, Cancer research.